This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): DVS-233, desvenlafaxine succinate, Ellefore
Description: Pristiq is a new chemical entity that is a dual serotonin and norepinephrine reuptake inhibitor (SNRI). It is the major metabolite of venlafaxine (Effexor).
Deal Structure: Pristiq was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
Impax Laboratories announced that beginning July 1, 2009, Impax Pharmaceuticals, the Company's specialty brand products division will co-promote Wyeth's Pristiq. Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.
In April 2010, Impax announced that it amended its 2008 co-promotion agreement with Wyeth, now a wholly owned subsidiary of Pfizer. Impax will now detail Lyrica CV for use as adjunctive therapy for...See full deal structure in Biomedtracker
Pink Sheet For Wyeth, More Delays And Setbacks
Additional information available to subscribers only: